PSCA CAR-T Cells With Inducible MyD88/CD40 for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR-T cell therapies for solid tumors face challenges with low persistence and sustained antitumor activity due to the lack of costimulatory molecules, leading to limited efficacy and potential toxicity from uncontrolled T cell activation.
Innovation Solution
Development of inducible MyD88/CD40 PSCA-CAR-T cells, which include a first polynucleotide encoding an inducible MyD88/CD40 polypeptide and a second polynucleotide encoding a prostate stem cell antigen (PSCA) chimeric antigen receptor, along with a heterogeneous T cell population, to provide controlled activation and prolonged persistence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional CAR-T cell therapy is used for solid tumors, then T cell activation occurs, but persistence and sustained antitumor activity are low due to lack of costimulatory molecules
Solution Approach 1:
The patent combines multiple functional elements into a single CAR-T cell construct: the PSCA antigen recognition domain, the MyD88 costimulatory domain, and the CD40 costimulatory domain are merged into one integrated receptor molecule. This merging allows simultaneous engagement of antigen recognition and dual costimulatory signaling, thereby enhancing both T cell persistence and antitumor activity without requiring separate molecular components.
Solution Approach 2:
The CAR-T cell receptor is constructed as a composite molecular structure integrating three distinct functional domains: the single-chain variable fragment (scFv) for antigen binding, the MyD88 intracellular signaling domain for costimulation, and the CD40 intracellular signaling domain for additional costimulatory signals. This composite structure enables the T cell to receive multiple simultaneous signals for enhanced persistence and activity.
2Reliability
If T cell activation is enhanced to improve antitumor activity, then therapeutic potency increases, but toxicity from uncontrolled activation may occur
Solution Approach 1:
The patent modifies the activation parameters of CAR-T cells by introducing controlled costimulatory signaling through the MyD88 and CD40 domains. This changes the activation threshold and duration, allowing sustained antitumor activity while preventing uncontrolled activation. The costimulatory domains provide regulated signaling that enhances therapeutic potency without causing excessive toxicity.
3Reliability
If CAR-T cell therapy is administered to achieve tumor elimination, then antitumor efficacy is needed, but low persistence limits sustained activity over time
Solution Approach 1:
The CAR-T cells are pre-engineered ex vivo with the integrated MyD88/CD40 costimulatory domains before administration to the patient. This preliminary genetic modification ensures that the cells possess enhanced persistence capabilities from the outset, allowing them to survive and maintain antitumor activity over extended periods without requiring additional in vivo interventions.
Data Source
AI summary
The technology relates generally to the field of immunology and relates in part to T cell compositions and methods for treating diseases and disorders associated with the presence of tumor cells that express prostate stem cell antigen.